{
  "subset": "indication",
  "disease": "Arrhythmogenic Right Ventricular Cardiomyopathy",
  "relation": "indication",
  "gold_drugs": [
    "flecainide pill"
  ],
  "seeds_initial": [
    "Sotalol",
    "Amiodarone",
    "Dofetilide",
    "Beta-Blockers",
    "Flecainide",
    "Propafenone",
    "Digoxin",
    "Ivabradine",
    "Lisinopril",
    "Carvedilol",
    "Atenolol",
    "Dexamethasone"
  ],
  "seed_history": [
    [
      "Sotalol",
      "Amiodarone",
      "Dofetilide",
      "Beta-Blockers",
      "Flecainide",
      "Propafenone",
      "Digoxin",
      "Ivabradine",
      "Lisinopril",
      "Carvedilol",
      "Atenolol",
      "Dexamethasone"
    ],
    [
      "Sotalol",
      "Dronedarone",
      "Amiodarone",
      "Procainamide",
      "Flecainide",
      "Beta-Blockers",
      "Adenosine",
      "Digoxin",
      "Quinidine",
      "Ivabradine",
      "Mexiletine",
      "Disopyramide"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_sotalol",
          "name": "Sotalol"
        },
        "score": 0.73,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "作用于离子通道并改善心脏电生理",
          "支持与不良反应的关联待进一步评估"
        ],
        "caveats": [
          "潜在的不良反应风险需明确",
          "靶点相似性可能导致相互作用"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_dronedarone",
          "name": "Dronedarone"
        },
        "score": 0.69,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "调节离子通道的机制支持电生理改善",
          "需注意潜在不良效应"
        ],
        "caveats": [
          "需要更多临床数据支持其靶点效果"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_amiodarone",
          "name": "Amiodarone"
        },
        "score": 0.65,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "影响β-肾上腺素受体支持心脏电生理稳定",
          "需确认长期疗效及适应症"
        ],
        "caveats": [
          "潜在安全隐患需重视"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target (Ion Channels)→Pathway→Disease (Arrhythmogenic Right Ventricular Cardiomyopathy)",
          "reason": "机制与心脏电生理关联明确，高支持权重的证据链"
        }
      ],
      "remaining_gaps": [
        "安全性问题关联多个药物，需进一步验证和明确"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "需更多研究以明确安全性和潜在不良反应"
      },
      {
        "role": "Skeptic",
        "patch": "关注靶点交叉与不良反应的临床后果"
      },
      {
        "role": "Explorer",
        "patch": "优先关注新型药物的独特机制，以避免重复性"
      }
    ],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Arrhythmogenic Right Ventricular Cardiomyopathy'. Return only names.\n\n# Prior guidance for Explorer:\n- 保持较强的安全性与有效性验证，为后续药物再评估提供基础\n\n# Heuristics:\n- When 心律失常患者: then 评估药物的长期疗效与安全性需同步进行\n- When 新药物引入: then 明确其机制及主要副作用，确保有可靠的临床支持"
}